APRINOIA Therapeutics Inc. is a clinical-stage biotechnology company engaged in protecting patients’ brain health and changing clinical outcomes for a range of neurodegenerative diseases by developing selective diagnostic tools and therapeutics. It is developing, APN-1607, as a positron emission tomography (PET) imaging tracer for the detection of 3R and 4R tau aggregates, which contribute to the pathogenesis of various tauopathies, including PSP, a rare neurodegenerative disease. It is also engaged in developing APN-1607 in progressive supranuclear palsy (PSP) and Alzheimer’s disease (AD) globally, independently or in collaboration with its partner. Its lead therapeutic product candidate, APNmAb005, is a humanized anti-tau antibody designed for the treatment of AD, non-AD primary tauopathies, including rare neurodegenerative disorders. Its PROTAC degrader offers a platform for the targeted degradation of toxic proteins that are causative in several neurodegenerative disorders.